SXTP 60 DEGREES PHARMACEUTICALS INC

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

WASHINGTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced today the webcast link and change of date for management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference in New York City, to Tuesday, September 9, 3:30 PM Eastern Time.

Dr. Geoff Dow, 60 Degrees Pharma CEO, will present live and management will conduct one-on-one meetings during the conference.

Event: H.C. Wainwright 27th Annual Global Investment Conference

Date: September 9, 2025

Time: 3:30 PM ET

Location: Lotte New York Palace Hotel

Webcast:

About 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018. ARAKODA is commercially available in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research and academic organizations in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at .

The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.

Media Contact:

Sheila A. Burke



(484) 667-6330

Investor Contact:

Patrick Gaynes



EN
03/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 60 DEGREES PHARMACEUTICALS INC

 PRESS RELEASE

60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Part...

60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership GoodRx to offer prescription savings of up to 30% for ARAKODA® (tafenoquine)Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company’s marketing strategyPartnership will improve the affordability of ARAKODA at over 70,000 pharmacies nationwide for people planning travel to malaria-endemic regions WASHINGTON, Feb. 02, 2026 (GLOBE NEWSWIRE) --  (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-bo...

 PRESS RELEASE

60 Degrees Pharmaceuticals Exercises License Option with Florida State...

60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use Company ready to commence regulatory process to secure access to U.S. market for Australian Chestnut Extract as a botanical product for non-prescription uses WASHINGTON, Jan. 28, 2026 (GLOBE NEWSWIRE) --  (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced it has exercised the option in its agreement with Florida State University (FS...

 PRESS RELEASE

60 Degrees Pharmaceuticals Announces Partnership with Runway Health to...

60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA® for Malaria Prevention Partnership adds a travel-focused consumer telehealth platform to the ARAKODA® marketing strategy, offering a new convenience to people planning travel to malaria-endemic regions of the worldARAKODA is the only FDA-approved, broad spectrum, once-weekly malaria prevention option for international travelers WASHINGTON, Jan. 22, 2026 (GLOBE NEWSWIRE) --  (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company...

 PRESS RELEASE

60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock S...

60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio WASHINGTON, Jan. 15, 2026 (GLOBE NEWSWIRE) -- 60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it will effect a one-for-four (1:4) reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on January 20, 2026, at 12:01 AM Eastern Time, before the opening of trading on The Nasdaq ...

 PRESS RELEASE

60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in...

60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State Further validates continuation of the B-FREE Study to evaluate the efficacy and safety of ARAKODA® (tafenoquine) for treatment of chronic babesiosisData support theory among specialists that Babesia infection may prolong recovery times in patients with chronic fatigue WASHINGTON, Dec. 29, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on develop...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch